%0 Journal Article
%T Targeted therapies in advanced biliary malignancies: a clinical review.
%A Grewal US
%A Gaddam SJ
%A Beg MS
%A Brown TJ
%J Expert Rev Anticancer Ther
%V 24
%N 9
%D 2024 Sep 4
%M 39083012
%F 3.627
%R 10.1080/14737140.2024.2387612
%X <B>UNASSIGNED: </B>Despite several therapeutic advancements, the proportion of patients with advanced biliary tract cancers (BTC) surviving 5 years from diagnosis remains dismal. The increasing recognition of targetable genetic alterations in BTCs has ushered in a new era in the treatment of these patients. Newer therapeutic agents targeting mutations such as isocitrate dehydrogenase (IDH), fibroblastic growth factor receptor (FGFR), human epidermal growth factor receptor (HER), and so on have established a new standard of care for treatment upon progression on frontline therapy in patients with disease harboring these mutations.<BR><B>UNASSIGNED: </B>The current review aims to concisely summarize progress with various targeted therapy options for BTC. We also briefly discuss future directions in clinical and translational research for the adoption of a personalized approach for the treatment of unresectable or advanced BTC.<BR><B>UNASSIGNED: </B>Several new agents continue to emerge as feasible treatment options for patients with advanced BTC harboring targetable mutations. There is a growing need to identify mechanisms to conquer primary and acquired resistance to these agents. The identification of potential biomarkers that predict response to targeted therapy may be helpful in adopting a more tailored approach. All patients receiving treatment for advanced BTC should undergo tissue genomic profiling at diagnosis.